# Phase 2b Study of NGM282 Extended Treatment in Patients With Primary Biliary Cirrhosis

> **NCT02135536** · PHASE2 · COMPLETED · sponsor: **NGM Biopharmaceuticals, Inc** · enrollment: 36 (actual)

## Conditions studied

- Primary Biliary Cirrhosis

## Interventions

- **BIOLOGICAL:** NGM282

## Key facts

- **NCT ID:** NCT02135536
- **Lead sponsor:** NGM Biopharmaceuticals, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-05
- **Primary completion:** 2016-02
- **Final completion:** 2016-02
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2017-03-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02135536

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02135536, "Phase 2b Study of NGM282 Extended Treatment in Patients With Primary Biliary Cirrhosis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02135536. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*